Alimera Sciences (NASDAQ:ALIM) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a report published on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

ALIM has been the topic of several other reports. Alliance Global Partners reaffirmed a neutral rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. HC Wainwright lowered shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 target price on the stock. in a research report on Tuesday, June 25th. Finally, Maxim Group reissued a hold rating on shares of Alimera Sciences in a report on Tuesday, June 25th.

Alimera Sciences Price Performance

Shares of Alimera Sciences stock opened at $5.54 on Tuesday. The company has a current ratio of 2.79, a quick ratio of 2.62 and a debt-to-equity ratio of 1.80. The firm has a fifty day simple moving average of $5.55 and a 200-day simple moving average of $4.58. The stock has a market capitalization of $290.24 million, a price-to-earnings ratio of -3.53 and a beta of 1.25. Alimera Sciences has a 1-year low of $2.61 and a 1-year high of $5.65.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The firm had revenue of $27.00 million for the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. On average, sell-side analysts expect that Alimera Sciences will post -0.13 earnings per share for the current year.

Institutional Trading of Alimera Sciences

Several institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC lifted its position in Alimera Sciences by 3.9% in the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock worth $1,010,000 after purchasing an additional 6,900 shares during the period. Rhumbline Advisers acquired a new position in shares of Alimera Sciences in the 2nd quarter valued at $113,000. Fifth Lane Capital LP bought a new position in shares of Alimera Sciences during the 1st quarter worth about $83,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Alimera Sciences during the 1st quarter valued at about $169,000. Finally, Bank of New York Mellon Corp bought a new stake in Alimera Sciences in the second quarter valued at about $344,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).